The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Results and Key Takeaways From GOG0213

Robert L. Coleman, MD, FACOG, FACS
Published Online: 7:29 PM, Sat March 28, 2015
Robert L. Coleman, MD, FACOG, FACS, professor, The University of Texas MD Anderson Cancer Center, discusses the results and key takeaways from GOG0213. This phase III trial compared carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary, and fallopian tube cancer.

<<< View more from SGO 2015

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.